Robert LeBoyer
Stock Analyst at Noble Capital Markets
(1.58)
# 3,710
Out of 5,172 analysts
18
Total ratings
33.33%
Success rate
0.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Reiterates: Outperform | $70 | $15.00 | +366.67% | 2 | Mar 20, 2025 | |
| NTRB Nutriband | Initiates: Outperform | $13 | $3.69 | +252.30% | 1 | Jan 22, 2025 | |
| GOVX GeoVax Labs | Maintains: Outperform | $150 → $250 | $1.47 | +16,906.80% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $60 | $6.73 | +791.53% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $6.52 | +820.25% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $2.88 | +247.22% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $1.46 | +858.90% | 1 | Feb 21, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $1.45 | +451.72% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $0.25 | +48,306.62% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $10.98 | - | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.06 | +195.57% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9,900,000 | $2.29 | +432,314,310.48% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $36.00 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $2.54 | +490.55% | 2 | Mar 8, 2018 |
Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $15.00
Upside: +366.67%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $3.69
Upside: +252.30%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $150 → $250
Current: $1.47
Upside: +16,906.80%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $6.73
Upside: +791.53%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $6.52
Upside: +820.25%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $2.88
Upside: +247.22%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.46
Upside: +858.90%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.45
Upside: +451.72%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.25
Upside: +48,306.62%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $10.98
Upside: -
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $4.06
Upside: +195.57%
Aug 24, 2020
Initiates: Buy
Price Target: $9,900,000
Current: $2.29
Upside: +432,314,310.48%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $36.00
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $2.54
Upside: +490.55%